Jody L. Green
Research Subjects
Jody L. Green has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Taryn Dailey-Govoni
Uprise Health, an IBH Company, Irvine, California. ORCID: https://orcid.org/
6 shared publications - Stephen F. Butler
Inflexxion, Inc., Newton, MA, USA
5 shared publications - Suzanne K. Vosburg
Inflexxion, an IBH Company, Costa Mesa, CA, USA
5 shared publications Taryn Dailey-Govoni
Uprise Health, Irvine, California
4 shared publications- Richard C. Dart
Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO, United States
3 shared publications - Jared Beaumont
Inflexxion, 2 Pk Plaza,Suite 1200, Irvine, CA 92614 USA
2 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (3) , 751-763
Buprenorphine Products for the Treatment of Pain: Relative Risk of Abuse and Related Clinical Outcomes Compared to Full μ-Opioid Agonist Medications
Introduction The objective of this study was to utilize real-world data from National Poison Data System (NPDS) to evaluate the relative risk of intentional use and subsequent outcomes following exposures to buprenorphine buccal film (BBF) compared to immediate-release (IR) and extended-release (ER) full agonist opioid (FAO) formulations, and buprenorphine transdermal patch (BTP). Methods A cross-sectional study design compared exposures that involved BBF to those that involved IR FAO, ER FAO, and BTP using real-world data from NPDS. Data included individuals age 18 years and older involved in exposures managed by US poison centers from 2020 to 2023. Descriptive statistics were used to summarize study groups, exposures, and outcomes. Relative risk was calculated for exposure reasons and clinical outcomes using BBF as reference group. Results Dataset included 276 BBF, 43,322 IR FAO, 2453 ER FAO, and 134 BTP exposures. Compared to BBF, significantly higher risks were found for both IR FAO and ER FAO for intentional abuse, intentional suspected suicide, significant medical outcome, hospital admission, and treated/evaluated and released level of care. Conclusion Findings from this study suggest that, compared to FAO, exposures to BBF managed by US poison centers were less likely to involve intentional abuse or suspected suicide, have a decreased risk of resulting in a life-threatening effect or death, and have a lower likelihood of subsequent hospital admission and emergency department visits. Along with published guidelines and medication labels (including boxed warnings), relative risks of intentional exposures and associated clinical outcomes should be considered when determining opioid therapy for pain management.
- 15 April 2026
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (3) , 751-763
Open AccessBuprenorphine Products for the Treatment of Pain: Relative Risk of Abuse and Related Clinical Outcomes Compared to Full μ-Opioid Agonist Medications
Introduction The objective of this study was to utilize real-world data from National Poison Data System (NPDS) to evaluate the relative risk of intentional use and subsequent outcomes following exposures to buprenorphine buccal film (BBF) compared to immediate-release (IR) and extended-release (ER) full agonist opioid (FAO) formulations, and buprenorphine transdermal patch (BTP). Methods A cross-sectional study design compared exposures that involved BBF to those that involved IR FAO, ER FAO, and BTP using real-world data from NPDS. Data included individuals age 18 years and older involved in exposures managed by US poison centers from 2020 to 2023. Descriptive statistics were used to summarize study groups, exposures, and outcomes. Relative risk was calculated for exposure reasons and clinical outcomes using BBF as reference group. Results Dataset included 276 BBF, 43,322 IR FAO, 2453 ER FAO, and 134 BTP exposures. Compared to BBF, significantly higher risks were found for both IR FAO and ER FAO for intentional abuse, intentional suspected suicide, significant medical outcome, hospital admission, and treated/evaluated and released level of care. Conclusion Findings from this study suggest that, compared to FAO, exposures to BBF managed by US poison centers were less likely to involve intentional abuse or suspected suicide, have a decreased risk of resulting in a life-threatening effect or death, and have a lower likelihood of subsequent hospital admission and emergency department visits. Along with published guidelines and medication labels (including boxed warnings), relative risks of intentional exposures and associated clinical outcomes should be considered when determining opioid therapy for pain management.
- Top Cited PapersOpen Access
- 2 February 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (2) , e2559479
Prevalence of Over-the-Counter and Prescription Medication Use in the US
Importance: In the US, reliance on over-the-counter (OTC) and prescription medications has important public health implications. Understanding the prevalence of medication use, overall and by specific medication, aids in regulatory decision-making and pharmacoeconomic evaluations and informs measures of benefits and risks. Objective: To estimate the current prevalence of OTC and prescription medication use in the US adult population. Design, Setting, and Participants: This survey study analyzed data collected via a population-based, online survey of the US adult population (June 2023 to April 2024). Participants were volunteer online panelists aged 18 years and older. Exposure: Use of any OTC or prescription medication. Main Outcomes and Measures: The primary outcome was prevalence of OTC and prescription medication use (overall and by specific medication), stratified by sex and age. Prevalence estimates were generated by calculating the proportion of the population reporting the key outcomes. Results: Of the 21 000 participants, 11 171 (53.2%) were female, and the mean (SD) age was 47.9 (17.5) years. Past-7-day prevalence of OTC or prescription medication use was 62.3% (13 073 individuals). The use of 5 or more medications was reported by 3425 participants (16.3%), and 690 (3.3%) reported taking 10 or more medications. Although use was higher among female individuals (7442 participants [66.6%]) than among male individuals (5631 participants [57.3%]), the patterns of increasing use and increasing number of medications with age were similar. The past-7-day prevalence of OTC medication use (9657 participants [46.0%]) was similar to that of prescription medications (9719 participants [46.3%]). Acetaminophen (6184 participants [29.4%]), ibuprofen (4693 participants [22.3%]), and aspirin (3323 participants [15.8%]) were the most reported medications used in the past 7 days. Six of the 10 most prevalent medications reported were available OTC. The most reported prescription medications were atorvastatin (1342 participants [6.4%]), lisinopril (1163 participants [5.5%]), levothyroxine (1086 participants [5.2%]), and amlodipine (965 participants [4.6%]). Conclusions and Relevance: In this 2023 to 2024 study, nearly 2 of 3 US adults reported medication use in the past 7 days. Past-7-day prevalence of OTC and prescription medication use was similar, demonstrating the reliance on these therapies and highlighting the importance of accessibility. Medication-specific prevalence allows for a better understanding of actual use and the ability to estimate potential benefits and risks associated with medication access or regulatory changes. Continued monitoring is necessary to measure the benefits and risks of regulatory decisions or other market changes that may affect medication access or use.
- 2 February 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (2) , e2559479
Top Cited PapersOpen AccessPrevalence of Over-the-Counter and Prescription Medication Use in the US
Importance: In the US, reliance on over-the-counter (OTC) and prescription medications has important public health implications. Understanding the prevalence of medication use, overall and by specific medication, aids in regulatory decision-making and pharmacoeconomic evaluations and informs measures of benefits and risks. Objective: To estimate the current prevalence of OTC and prescription medication use in the US adult population. Design, Setting, and Participants: This survey study analyzed data collected via a population-based, online survey of the US adult population (June 2023 to April 2024). Participants were volunteer online panelists aged 18 years and older. Exposure: Use of any OTC or prescription medication. Main Outcomes and Measures: The primary outcome was prevalence of OTC and prescription medication use (overall and by specific medication), stratified by sex and age. Prevalence estimates were generated by calculating the proportion of the population reporting the key outcomes. Results: Of the 21 000 participants, 11 171 (53.2%) were female, and the mean (SD) age was 47.9 (17.5) years. Past-7-day prevalence of OTC or prescription medication use was 62.3% (13 073 individuals). The use of 5 or more medications was reported by 3425 participants (16.3%), and 690 (3.3%) reported taking 10 or more medications. Although use was higher among female individuals (7442 participants [66.6%]) than among male individuals (5631 participants [57.3%]), the patterns of increasing use and increasing number of medications with age were similar. The past-7-day prevalence of OTC medication use (9657 participants [46.0%]) was similar to that of prescription medications (9719 participants [46.3%]). Acetaminophen (6184 participants [29.4%]), ibuprofen (4693 participants [22.3%]), and aspirin (3323 participants [15.8%]) were the most reported medications used in the past 7 days. Six of the 10 most prevalent medications reported were available OTC. The most reported prescription medications were atorvastatin (1342 participants [6.4%]), lisinopril (1163 participants [5.5%]), levothyroxine (1086 participants [5.2%]), and amlodipine (965 participants [4.6%]). Conclusions and Relevance: In this 2023 to 2024 study, nearly 2 of 3 US adults reported medication use in the past 7 days. Past-7-day prevalence of OTC and prescription medication use was similar, demonstrating the reliance on these therapies and highlighting the importance of accessibility. Medication-specific prevalence allows for a better understanding of actual use and the ability to estimate potential benefits and risks associated with medication access or regulatory changes. Continued monitoring is necessary to measure the benefits and risks of regulatory decisions or other market changes that may affect medication access or use.
- Open Access
- 1 February 2026
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 22 (1) , 77-89
Systematic review of real-world data associated with opioid scheduling and nonmedical use
Objective: In the context of increased use of buprenorphine for pain management, comparison of real-world data (RWD) on prescription opioid nonmedical use (NMU) based on their controlled substance schedule may assist providers in providing effective pain management therapy while mitigating the risk of opioid NMU. Design: A systematic literature review of articles reporting RWD on prescription opioid NMU involving Schedule II (CII), Schedule III (CIII), and Schedule IV (CIV) opioid medications was conducted using PubMed®. Patients/participants: Human RWD collected in the United States from January 2010 to December 2023. Main outcome measure(s): Articles reporting RWD of prescription opioid NMU. Exclusions included buprenorphine/methadone medications for opioid use disorder, chronic use, or overdose without clearly established NMU (could not rule out legitimate medical use). Results: There were 2,585 articles screened for inclusion, 102 articles were assessed with a validated data extraction form, and 16 articles were reviewed that compared NMU and/or secondary NMU-related outcomes. Of these, only five articles contained RWD on NMU; all showed more NMU associated with CII than CIII or CIV opioids. Two articles evaluated buprenorphine (CIII) for analgesia and found lower rates of CIII NMU than comparator CII opioids. Conclusions: Results of this systematic review support the differentiation in scheduling between CII and CIII/CIV opioid medications with RWD. This study also reveals a research gap in comparing CIII opioid medications for analgesia to CII and CIV opioids, an area of current and future interest, considering the growing use of buprenorphine for pain management, along with initiatives to curb opioid NMU.
- 1 February 2026
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 22 (1) , 77-89
Open AccessSystematic review of real-world data associated with opioid scheduling and nonmedical use
Objective: In the context of increased use of buprenorphine for pain management, comparison of real-world data (RWD) on prescription opioid nonmedical use (NMU) based on their controlled substance schedule may assist providers in providing effective pain management therapy while mitigating the risk of opioid NMU. Design: A systematic literature review of articles reporting RWD on prescription opioid NMU involving Schedule II (CII), Schedule III (CIII), and Schedule IV (CIV) opioid medications was conducted using PubMed®. Patients/participants: Human RWD collected in the United States from January 2010 to December 2023. Main outcome measure(s): Articles reporting RWD of prescription opioid NMU. Exclusions included buprenorphine/methadone medications for opioid use disorder, chronic use, or overdose without clearly established NMU (could not rule out legitimate medical use). Results: There were 2,585 articles screened for inclusion, 102 articles were assessed with a validated data extraction form, and 16 articles were reviewed that compared NMU and/or secondary NMU-related outcomes. Of these, only five articles contained RWD on NMU; all showed more NMU associated with CII than CIII or CIV opioids. Two articles evaluated buprenorphine (CIII) for analgesia and found lower rates of CIII NMU than comparator CII opioids. Conclusions: Results of this systematic review support the differentiation in scheduling between CII and CIII/CIV opioid medications with RWD. This study also reveals a research gap in comparing CIII opioid medications for analgesia to CII and CIV opioids, an area of current and future interest, considering the growing use of buprenorphine for pain management, along with initiatives to curb opioid NMU.
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-11
Evaluation of Abuse Deterrent Formulations of Oxycodone Products: Real-World Data from an Enriched Population of Substance Users Assessed with the Addiction Severity Index-Multimedia Version (ASI-MV®)
Purpose: The study purpose was to evaluate real-world data on routes of administration (ROAs) employed for nonmedical use (NMU) of XTAMPZA ER compared to other oxycodone extended-release (ER) and oxycodone immediate-release (IR) formulations in a population of adults assessed for substance use. Patients and Methods: A cross-sectional observational study was conducted among adults assessed for substance use and treatment planning using the Addiction Severity Index-Multimedia Version (ASI-MV®) from July 2016 through December 2023. Demographic and substance use history data were summarized to characterize the sample. The primary outcome measure was the prevalence of past 30-day non-oral NMU, assessed first by using Pearson’s chi-square to test differences in prevalence, then by calculating the proportional reporting ratios (PRR) to determine if specific non-oral ROAs were more or less likely to be used for XTAMPZA ER NMU versus comparators. Results: The prevalence of non-oral ROA cases was significantly higher among other oxycodone ER cases (2221/4935, 45.0%) and oxycodone IR cases (10,598/20,394, 52.0%) compared to XTAMPZA ER cases (31/141, 22.0%)(X2=29.43, p< 0.0001 and X2=50.41, p< 0.0001, respectively). Compared to other oxycodone ER, XTAMPZA ER had a 33% lower risk of snorting (PRR: 0.67, 95% CI: 0.47, 0.95) and a 63% lower risk of injecting (PRR: 0.37, 95% CI: 0.19, 0.71). Compared to oxycodone IR, XTAMPZA ER had a 46% lower risk of snorting (PRR: 0.54, 95% CI: 0.38, 0.77) and a 66% lower risk of injecting (PRR: 0.44, 95% CI: 0.23, 0.86). Conclusion: Opioid medications can provide valuable patient benefits with risks best mitigated by using formulations associated with lower likelihood of NMU, particularly via higher-risk non-oral ROAs. These study findings suggest that XTAMPZA ER has a lower risk of NMU via non-oral ROA compared to other oxycodone ER and oxycodone IR products in an enriched population of substance users.
- 1 January 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-11
Open AccessEvaluation of Abuse Deterrent Formulations of Oxycodone Products: Real-World Data from an Enriched Population of Substance Users Assessed with the Addiction Severity Index-Multimedia Version (ASI-MV®)
Purpose: The study purpose was to evaluate real-world data on routes of administration (ROAs) employed for nonmedical use (NMU) of XTAMPZA ER compared to other oxycodone extended-release (ER) and oxycodone immediate-release (IR) formulations in a population of adults assessed for substance use. Patients and Methods: A cross-sectional observational study was conducted among adults assessed for substance use and treatment planning using the Addiction Severity Index-Multimedia Version (ASI-MV®) from July 2016 through December 2023. Demographic and substance use history data were summarized to characterize the sample. The primary outcome measure was the prevalence of past 30-day non-oral NMU, assessed first by using Pearson’s chi-square to test differences in prevalence, then by calculating the proportional reporting ratios (PRR) to determine if specific non-oral ROAs were more or less likely to be used for XTAMPZA ER NMU versus comparators. Results: The prevalence of non-oral ROA cases was significantly higher among other oxycodone ER cases (2221/4935, 45.0%) and oxycodone IR cases (10,598/20,394, 52.0%) compared to XTAMPZA ER cases (31/141, 22.0%)(X2=29.43, p< 0.0001 and X2=50.41, p< 0.0001, respectively). Compared to other oxycodone ER, XTAMPZA ER had a 33% lower risk of snorting (PRR: 0.67, 95% CI: 0.47, 0.95) and a 63% lower risk of injecting (PRR: 0.37, 95% CI: 0.19, 0.71). Compared to oxycodone IR, XTAMPZA ER had a 46% lower risk of snorting (PRR: 0.54, 95% CI: 0.38, 0.77) and a 66% lower risk of injecting (PRR: 0.44, 95% CI: 0.23, 0.86). Conclusion: Opioid medications can provide valuable patient benefits with risks best mitigated by using formulations associated with lower likelihood of NMU, particularly via higher-risk non-oral ROAs. These study findings suggest that XTAMPZA ER has a lower risk of NMU via non-oral ROA compared to other oxycodone ER and oxycodone IR products in an enriched population of substance users.
- Open Access
- 1 August 2024
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 20 (4) , 281-288
Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data
Objective: The United States (US) opioid epidemic is a continued burden on the healthcare system and on the lives of individuals affected by the consequences of opioid abuse/misuse. The objective of this study was to use real-world data from intentional abuse/misuse exposures managed by US poison centers to compare clinical outcomes and quantify healthcare costs among three study cohorts: exposures that involved Xtampza ER®, other oxycodone extended-release (ER), and oxycodone immediate-release (IR). Study design: A real-world, observational study. Main outcome measures: Descriptive statistics were used to describe patient and exposure characteristics. Drug utilization-adjusted rates of intentional abuse/misuse and clinical outcomes were used to determine relative risk. Healthcare cost estimates were calculated by extrapolating average charge per opioid-related disorder emergency department (ED) visit and per inpatient stay based upon case disposition rates, adjusted for population and drug utilization. Results: Compared to Xtampza ER, exposures that involved other oxycodone ER were 7.4 times more likely to be intentional abuse/misuse, 25.9 times more likely to result in major effect or death, 9.7 times more likely to require a visit to the ED, and 14.3 times more likely to result in hospital admission. Similar results were found for oxycodone IR when compared to Xtampza ER. Conclusions: This study is the first of its kind to synthesize clinical outcomes with opioid-related healthcare costs, suggesting that even when Xtampza ER is abused/misused, the rates of major effect/death, ED visits, and hospital admissions were significantly lower than those for other oxycodone-containing medications, resulting in relatively low downstream opioid-related healthcare costs.
- 1 August 2024
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 20 (4) , 281-288
Open AccessOpioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data
Objective: The United States (US) opioid epidemic is a continued burden on the healthcare system and on the lives of individuals affected by the consequences of opioid abuse/misuse. The objective of this study was to use real-world data from intentional abuse/misuse exposures managed by US poison centers to compare clinical outcomes and quantify healthcare costs among three study cohorts: exposures that involved Xtampza ER®, other oxycodone extended-release (ER), and oxycodone immediate-release (IR). Study design: A real-world, observational study. Main outcome measures: Descriptive statistics were used to describe patient and exposure characteristics. Drug utilization-adjusted rates of intentional abuse/misuse and clinical outcomes were used to determine relative risk. Healthcare cost estimates were calculated by extrapolating average charge per opioid-related disorder emergency department (ED) visit and per inpatient stay based upon case disposition rates, adjusted for population and drug utilization. Results: Compared to Xtampza ER, exposures that involved other oxycodone ER were 7.4 times more likely to be intentional abuse/misuse, 25.9 times more likely to result in major effect or death, 9.7 times more likely to require a visit to the ED, and 14.3 times more likely to result in hospital admission. Similar results were found for oxycodone IR when compared to Xtampza ER. Conclusions: This study is the first of its kind to synthesize clinical outcomes with opioid-related healthcare costs, suggesting that even when Xtampza ER is abused/misused, the rates of major effect/death, ED visits, and hospital admissions were significantly lower than those for other oxycodone-containing medications, resulting in relatively low downstream opioid-related healthcare costs.
- Open Access
- 1 June 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (6) , e16996
Characterizing the Experience of Tapentadol Nonmedical Use: Mixed Methods Study
Background: The prevalence of abuse, diversion, and web-based endorsement of tapentadol (extended-release [ER], immediate-release [IR]) has been characterized as low compared with other prescription opioids. Little is known about individual experience with tapentadol nonmedical use (NMU). Objective: This study aims to pilot web-based survey technologies to investigate the motivation for tapentadol NMU, sources of procurement, routes of administration, tampering methods, doses used, and impressions of tapentadol products (Nucynta and Nucynta ER). Methods: Recruitment flyers and banner advertisements were placed on the Bluelight website [DragonByte Technologies Ltd] with a link to a web-based survey (Qualtrics) designed to query about individuals' lifetime tapentadol NMU. This web-based survey was followed by an interactive web-based chat (Cryptocat) with respondents who were willing to be contacted. Respondents were queried about sources for obtaining tapentadol, motives for use, routes of administration, tampering methods, drugs used in combination, tablet strengths and dosages, and reasons for continued or discontinued use. Desirability and attractiveness for NMU was rated. Results: Web-based recruitment successfully attracted difficult-to-find study participants. A total of 78 participants reported that tapentadol was obtained from friends and family (ER 11/30, 37%; IR 18/67, 27%), the internet (ER 11/30, 37%; IR 12/67, 18%) or participants' own prescriptions from a doctor (ER 9/30, 30%; IR 17/67, 25%). It was used nonmedically for pain relief (ER 18/30, 60%; IR 33/67, 49%) and multiple psychotropic effects, including relaxation (ER 13/30, 43%; IR 29/67, 43%), reduction in depression or anxiety (ER 7/30, 23%; IR 30/67, 45%), or getting high (ER 12/30, 40%; IR 33/67, 49%). Tapentadol was primarily swallowed (ER 22/30, 73%; IR 55/67, 82%), although snorting (ER 2/30, 7%; IR 8/67, 12%) and injection (ER 2/30, 7%; IR 5/67, 8%) were also reported. The preferred dose for NMU was 100 mg (both ER and IR). The participants reported tapentadol use with benzodiazepines (ER 12/21, 57%; IR 28/47, 60%). Most participants had discontinued tapentadol NMU at the time of survey completion (ER 22/30, 73%; IR 55/67, 82%). Reasons for discontinued ER NMU included side effects (10/22, 46%) and lack of effective treatment (10/22, 46%). Reasons for discontinued IR NMU included lack of access (26/55, 47%) and better NMU options (IR 21/55, 38%). Few individuals were willing to divulge identifying information about themselves for the interactive chat (8/78, 10%), demonstrating the strength of anonymous, web-based surveys. Interactive chat supported the survey findings. A subgroup of participants (4/78, 5%) reported hallucinogenic side effects with high doses. Conclusions: Web-based surveys can successfully recruit individuals who report drug NMU and those who are difficult to find. Tapentadol NMU appears to occur primarily for pain relief and for its psychotropic effects. Although it was liked by some, tapentadol did not receive a robust pattern of endorsement for NMU.
- 1 June 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (6) , e16996
Open AccessCharacterizing the Experience of Tapentadol Nonmedical Use: Mixed Methods Study
Background: The prevalence of abuse, diversion, and web-based endorsement of tapentadol (extended-release [ER], immediate-release [IR]) has been characterized as low compared with other prescription opioids. Little is known about individual experience with tapentadol nonmedical use (NMU). Objective: This study aims to pilot web-based survey technologies to investigate the motivation for tapentadol NMU, sources of procurement, routes of administration, tampering methods, doses used, and impressions of tapentadol products (Nucynta and Nucynta ER). Methods: Recruitment flyers and banner advertisements were placed on the Bluelight website [DragonByte Technologies Ltd] with a link to a web-based survey (Qualtrics) designed to query about individuals' lifetime tapentadol NMU. This web-based survey was followed by an interactive web-based chat (Cryptocat) with respondents who were willing to be contacted. Respondents were queried about sources for obtaining tapentadol, motives for use, routes of administration, tampering methods, drugs used in combination, tablet strengths and dosages, and reasons for continued or discontinued use. Desirability and attractiveness for NMU was rated. Results: Web-based recruitment successfully attracted difficult-to-find study participants. A total of 78 participants reported that tapentadol was obtained from friends and family (ER 11/30, 37%; IR 18/67, 27%), the internet (ER 11/30, 37%; IR 12/67, 18%) or participants' own prescriptions from a doctor (ER 9/30, 30%; IR 17/67, 25%). It was used nonmedically for pain relief (ER 18/30, 60%; IR 33/67, 49%) and multiple psychotropic effects, including relaxation (ER 13/30, 43%; IR 29/67, 43%), reduction in depression or anxiety (ER 7/30, 23%; IR 30/67, 45%), or getting high (ER 12/30, 40%; IR 33/67, 49%). Tapentadol was primarily swallowed (ER 22/30, 73%; IR 55/67, 82%), although snorting (ER 2/30, 7%; IR 8/67, 12%) and injection (ER 2/30, 7%; IR 5/67, 8%) were also reported. The preferred dose for NMU was 100 mg (both ER and IR). The participants reported tapentadol use with benzodiazepines (ER 12/21, 57%; IR 28/47, 60%). Most participants had discontinued tapentadol NMU at the time of survey completion (ER 22/30, 73%; IR 55/67, 82%). Reasons for discontinued ER NMU included side effects (10/22, 46%) and lack of effective treatment (10/22, 46%). Reasons for discontinued IR NMU included lack of access (26/55, 47%) and better NMU options (IR 21/55, 38%). Few individuals were willing to divulge identifying information about themselves for the interactive chat (8/78, 10%), demonstrating the strength of anonymous, web-based surveys. Interactive chat supported the survey findings. A subgroup of participants (4/78, 5%) reported hallucinogenic side effects with high doses. Conclusions: Web-based surveys can successfully recruit individuals who report drug NMU and those who are difficult to find. Tapentadol NMU appears to occur primarily for pain relief and for its psychotropic effects. Although it was liked by some, tapentadol did not receive a robust pattern of endorsement for NMU.
- 22 April 2022
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 57 (7) , 1097-1103
Changes in Hydrocodone Misuse Exposures Reported to U.S. Poison Centers Following Rescheduling in 2014
In 2014, the Drug Enforcement Administration rescheduled hydrocodone combination products to Schedule II to reduce nonmedical use and diversion.The impact of rescheduling was assessed using quarter...
- 22 April 2022
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 57 (7) , 1097-1103
Changes in Hydrocodone Misuse Exposures Reported to U.S. Poison Centers Following Rescheduling in 2014
In 2014, the Drug Enforcement Administration rescheduled hydrocodone combination products to Schedule II to reduce nonmedical use and diversion.The impact of rescheduling was assessed using quarter...
- Open Access
- 11 September 2021
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 14, 100376
Characterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit
- 11 September 2021
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 14, 100376
Open AccessCharacterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 14, 1773-1783
Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®)
Purpose: The purpose of this study was to evaluate real-world data related to past 30-day nonmedical use (NMU) and routes of administration of Xtampza® ER and comparator oxycodone medications in the US as captured within the Addiction Severity Index-Multimedia Version® (ASI-MV®). Methods: Data were collected from July 2016 through December 2019 from 647 centers located in 44 states using the ASI-MV, a clinical instrument used to evaluate substance use and treatment planning. Demographic characteristics were assessed using Pearson’s chi-square test for categorical data and quarterly NMU rates were calculated. Distribution of route of administration was studied using a proportional reporting ratio (PRR) analysis. Results: Of 192,810 assessments, 42,279 (21.9%) indicated past 30-day NMU of at least one prescription opioid, including Xtampza ER (N=73, 0.2%), other oxycodone ER (n=3802, 9.0%) and oxycodone IR (n=14,579, 34.5%). All quarterly Xtampza ER NMU rates per 100 ASI-MV assessments were significantly lower than those for other oxycodone ER and oxycodone IR. Overall, quarterly Xtampza ER NMU drug utilization adjusted rates were significantly lower than quarterly rates observed for other oxycodone ER NMU but not consistently significantly lower than oxycodone IR NMU. Although not all statistically significant, all ratios from the PRR analysis were less than 1.0, indicating that rates of use of any alternate route, any non-oral route, snorting, and injecting were higher for other oxycodone ER and oxycodone IR than for Xtampza ER. Conclusion: Xtampza ER had significantly lower rates of NMU than other oxycodone ER products and oxycodone IR products, as well as significantly lower rates of non-oral NMU than oxycodone IR products, in a population of individuals seeking substance abuse treatment. Understanding risks associated with different opioid medications is important for prescribers as they manage risks of opioid misuse and abuse with effective pain therapy.
- 1 June 2021
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 14, 1773-1783
Open AccessNonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®)
Purpose: The purpose of this study was to evaluate real-world data related to past 30-day nonmedical use (NMU) and routes of administration of Xtampza® ER and comparator oxycodone medications in the US as captured within the Addiction Severity Index-Multimedia Version® (ASI-MV®). Methods: Data were collected from July 2016 through December 2019 from 647 centers located in 44 states using the ASI-MV, a clinical instrument used to evaluate substance use and treatment planning. Demographic characteristics were assessed using Pearson’s chi-square test for categorical data and quarterly NMU rates were calculated. Distribution of route of administration was studied using a proportional reporting ratio (PRR) analysis. Results: Of 192,810 assessments, 42,279 (21.9%) indicated past 30-day NMU of at least one prescription opioid, including Xtampza ER (N=73, 0.2%), other oxycodone ER (n=3802, 9.0%) and oxycodone IR (n=14,579, 34.5%). All quarterly Xtampza ER NMU rates per 100 ASI-MV assessments were significantly lower than those for other oxycodone ER and oxycodone IR. Overall, quarterly Xtampza ER NMU drug utilization adjusted rates were significantly lower than quarterly rates observed for other oxycodone ER NMU but not consistently significantly lower than oxycodone IR NMU. Although not all statistically significant, all ratios from the PRR analysis were less than 1.0, indicating that rates of use of any alternate route, any non-oral route, snorting, and injecting were higher for other oxycodone ER and oxycodone IR than for Xtampza ER. Conclusion: Xtampza ER had significantly lower rates of NMU than other oxycodone ER products and oxycodone IR products, as well as significantly lower rates of non-oral NMU than oxycodone IR products, in a population of individuals seeking substance abuse treatment. Understanding risks associated with different opioid medications is important for prescribers as they manage risks of opioid misuse and abuse with effective pain therapy.
- Open Access
- 25 January 2021
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11
Characterizing Pathways of Non-oral Prescription Stimulant Non-medical Use Among Adults Recruited From Reddit
Objective: Prescription stimulant non-medical use (NMU) is a national predicament. While the risks of prescription stimulant NMU have been considered, less is known about non-oral use. To focus on this gap, a sample of adults with non-oral prescription stimulant NMU within the last 5-years was recruited. The purpose of the present study was to characterize the pathways and substance transitions associated with prescription stimulant NMU and non-oral prescription stimulant NMU in this unique sample of adults.Methods: Adults (n = 225) reporting non-oral prescription stimulant NMU within the last 5 years were recruited to complete an online survey by banner ads placed on the Reddit website between February and September 2019. After completion of the survey, a second study consisting of an in-depth telephone interview was conducted with 23 participants: interviews took place between July and September 2019. Data reported here include substance, route of administration and class transitions, as well as qualitative data from the interviews.Results: Approximately 1 in 5 began their substance use trajectory with prescription stimulants (19.1%). Other than marijuana, most exposures to illicit substances occurred after both initial prescription stimulant NMU and initial non-oral prescription stimulant NMU. The most frequently reported route of administration transition was from oral use to snorting (n = 158, 70.2%), however, other route of administration transitions included oral use to injection drug use (n = 14, 6%). In-depth interviews elaborated upon these transitions and indicated that prescription stimulant NMU was consequential to substance use pathways.Conclusions: Oral prescription stimulant NMU was a precursor to non-oral prescription stimulant NMU. Non-oral prescription stimulant NMU was a precursor to illicit substance use, suggesting that prescription stimulant NMU impacts substance use pathways and revealing opportunities for intervention.
- 25 January 2021
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11
Open AccessCharacterizing Pathways of Non-oral Prescription Stimulant Non-medical Use Among Adults Recruited From Reddit
Objective: Prescription stimulant non-medical use (NMU) is a national predicament. While the risks of prescription stimulant NMU have been considered, less is known about non-oral use. To focus on this gap, a sample of adults with non-oral prescription stimulant NMU within the last 5-years was recruited. The purpose of the present study was to characterize the pathways and substance transitions associated with prescription stimulant NMU and non-oral prescription stimulant NMU in this unique sample of adults.Methods: Adults (n = 225) reporting non-oral prescription stimulant NMU within the last 5 years were recruited to complete an online survey by banner ads placed on the Reddit website between February and September 2019. After completion of the survey, a second study consisting of an in-depth telephone interview was conducted with 23 participants: interviews took place between July and September 2019. Data reported here include substance, route of administration and class transitions, as well as qualitative data from the interviews.Results: Approximately 1 in 5 began their substance use trajectory with prescription stimulants (19.1%). Other than marijuana, most exposures to illicit substances occurred after both initial prescription stimulant NMU and initial non-oral prescription stimulant NMU. The most frequently reported route of administration transition was from oral use to snorting (n = 158, 70.2%), however, other route of administration transitions included oral use to injection drug use (n = 14, 6%). In-depth interviews elaborated upon these transitions and indicated that prescription stimulant NMU was consequential to substance use pathways.Conclusions: Oral prescription stimulant NMU was a precursor to non-oral prescription stimulant NMU. Non-oral prescription stimulant NMU was a precursor to illicit substance use, suggesting that prescription stimulant NMU impacts substance use pathways and revealing opportunities for intervention.